Bright Minds Biosciences (DRUG) Cash & Current Investments (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Cash & Current Investments data on file, last reported at $226.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 481.39% year-over-year to $226.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.0 million (up 481.39% YoY) and the FY2025 annual result came in at $60.3 million, up 1316.87% from the prior year.
• Cash & Current Investments grew to $226.0 million in Q1 2026, from $64.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $226.0 million in Q1 2026 to a low of $4.3 million in Q3 2024.
• A 5-year average of $31.6 million and a median of $8.3 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 61.92% — and 2025, when it jumped 1316.87%.
• Tracing DRUG's Cash & Current Investments over 5 years: stood at $8.3 million in 2022, then plunged by 39.57% to $5.0 million in 2023, then jumped by 725.19% to $41.5 million in 2024, then jumped by 54.14% to $64.0 million in 2025, then soared by 253.17% to $226.0 million in 2026.
• The last three Cash & Current Investments figures came in at $226.0 million (Q1 2026), $64.0 million (Q4 2025), and $60.3 million (Q3 2025), per Business Quant data.